<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04024501</url>
  </required_header>
  <id_info>
    <org_study_id>D5495C00005</org_study_id>
    <nct_id>NCT04024501</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition</brief_title>
  <official_title>A Randomised, Single-dose, 5-period, 5-treatment, Crossover Study to Assess the Relative Bioavailability of 3 Different Extended-release Formulations of Verinurad in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to assess the relative bioavailability between the (extended-release)&#xD;
      ER8 capsule formulation (the formulation that is currently used for verinurad development)&#xD;
      given under fasted conditions and 2 new capsule formulations of verinurad (A-capsule and&#xD;
      B-capsule) given under fed or fasted conditions. All three capsules target an 8-hour release&#xD;
      profile (extended-release). The highest dose (12 mg) currently tested in participants will be&#xD;
      tested in this study. The study is designed to provide information to optimize the verinurad&#xD;
      part of a fixed dose combination capsule to be used in future development.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomised, open-label, single-dose, 5-period, 5-treatment, crossover&#xD;
      study in healthy male and female participants, performed at a single study centre. This study&#xD;
      is intended to assess the relative bioavailability between the ER8 capsule formulation (the&#xD;
      formulation that is currently used for verinurad development) given under fasted conditions&#xD;
      and 2 new capsule formulation of verinurad (A-capsule and B-capsule) given under fed or&#xD;
      fasted conditions. All three capsules target an 8-hour release profile (extended-release).&#xD;
      The highest dose (12 mg) currently tested in participants will be tested in this study. The&#xD;
      study is designed to provide information to optimize the verinurad part of a fixed dose&#xD;
      combination capsule to be used in future development. The study will comprise: a screening&#xD;
      period of maximum 28 days; five treatment periods during which participants will be resident&#xD;
      from the morning of the day before dosing with verinurad (Day -1) until at least 72 hours&#xD;
      after dosing; discharged on the morning of Day 4 of each Treatment Period; and a follow-up&#xD;
      Visit within 7 to 14 days after the last administration of verinurad. There will be a minimum&#xD;
      washout period of 5 days between each dose administration. A total of 25 healthy male and&#xD;
      female participants will be randomised into this study. Each participant will receive five&#xD;
      single-dose treatments of 12 mg verinurad with 240 mL water, following an overnight fast of&#xD;
      at least 10 hours. Participants will follow an overnight fast of at least 10 hours before the&#xD;
      dosing procedures: for the fed dosing, a high-fat, high-calorie standard breakfast will be&#xD;
      served 30 minutes before the planned administration of verinurad to be consumed in full at&#xD;
      least 5 minutes before dosing; for the fasted dosing, no breakfast will be served. A meal can&#xD;
      be given 4 hours after administration of verinurad for both dosing states. The duration of&#xD;
      the study is expected to be approximately 9 weeks for each individual participant (including&#xD;
      the 28-day screening period).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2019</start_date>
  <completion_date type="Actual">September 18, 2019</completion_date>
  <primary_completion_date type="Actual">September 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC)</measure>
    <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
    <description>To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC From Time 0 to the Last Quantifiable Concentration (AUC0-t) for the Analysis of PK Parameter</measure>
    <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
    <description>To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for the Analysis of PK Parameter</measure>
    <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
    <description>To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC From Time 0 to 24 Hours Post Dose (AUC0-24) for the Analysis of PK Parameter</measure>
    <time_frame>Pre-dose and up to 24-hours Post-dose</time_frame>
    <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for the Analysis of PK Parameter</measure>
    <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
    <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) for the Analysis of PK Parameter</measure>
    <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
    <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for the Analysis of PK Parameter</measure>
    <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
    <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRT) for the Analysis of PK Parameter</measure>
    <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
    <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Last Quantifiable Plasma Concentration (Tlast) for the Analysis of PK Parameter</measure>
    <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
    <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Intravenous Dosing) (Vss/F) for the Analysis of PK Parameter</measure>
    <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
    <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for the Analysis of PK Parameter</measure>
    <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
    <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>From screening (Day -28 to Day -2) till follow-up visit (7 to 14 days post-final dose)</time_frame>
    <description>To assess AEs as variable of safety and tolerability of single doses of verinurad in healthy participants.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verinurad ER8 capsule formulation (fasted)</intervention_name>
    <description>Each participant will receive single-dose treatment of 12 mg verinurad ER8 capsule with 240 mL water, following an overnight fast of at least 10 hours.</description>
    <arm_group_label>Treatment 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verinurad A-capsule formulation (fasted)</intervention_name>
    <description>Each participant will receive single-dose treatment of 12 mg verinurad A-capsule with 240 mL water, following an overnight fast of at least 10 hours.</description>
    <arm_group_label>Treatment 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verinurad A-capsule formulation (fed)</intervention_name>
    <description>Each participant will receive single dose treatment of 12 mg verinurad A-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).</description>
    <arm_group_label>Treatment 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verinurad B-capsule formulation (fasted)</intervention_name>
    <description>Each participant will receive single-dose treatment of 12 mg verinurad B-capsule with 240 mL water, following an overnight fast of at least 10 hours.</description>
    <arm_group_label>Treatment 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verinurad B-capsule formulation (fed)</intervention_name>
    <description>Each participant will receive single dose treatment of 12 mg verinurad B-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).</description>
    <arm_group_label>Treatment 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated, written informed consent prior to any study specific&#xD;
             procedures.&#xD;
&#xD;
          2. Healthy male and female participants aged 18 to 50 years with suitable veins for&#xD;
             cannulation or repeated venepuncture.&#xD;
&#xD;
          3. Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no&#xD;
             more than 100 kg.&#xD;
&#xD;
          4. Females must have a negative pregnancy test at screening and on admission to the unit&#xD;
             and must be:&#xD;
&#xD;
        (1) not pregnant or currently lactating or breastfeeding. (2) of non-childbearing&#xD;
        potential, confirmed at screening by fulfilling one of the following criteria: (i)&#xD;
        postmenopausal defined as amenorrhoea for at least 12 months or more following cessation of&#xD;
        all exogenous hormonal treatments and FSH levels in the postmenopausal range (FSH levels &gt;&#xD;
        40 IU/mL).&#xD;
&#xD;
        (ii) documentation of irreversible surgical sterilization by hysterectomy, bilateral&#xD;
        oophorectomy or bilateral salpingectomy but not tubal ligation.&#xD;
&#xD;
        (3) OR if of childbearing potential must be willing to use an acceptable method of&#xD;
        contraception to avoid pregnancy for the entire study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of gout or any clinically significant disease or disorder which, in the&#xD;
             opinion of the Principal Investigator (PI), may either put the volunteer at risk&#xD;
             because of participation in the study, or influence the results or the volunteer's&#xD;
             ability to participate in the study.&#xD;
&#xD;
          2. Any clinically important illness, medical/surgical procedure or trauma within 4 weeks&#xD;
             of the first administration of verinurad.&#xD;
&#xD;
          3. History or presence of gastrointestinal (GI), hepatic or renal disease, or any other&#xD;
             condition known to interfere with absorption, distribution, metabolism, or excretion&#xD;
             of drugs.&#xD;
&#xD;
          4. Any clinically important abnormalities in clinical chemistry, haematology or&#xD;
             urinalysis results as judged by the Investigator at screening and first admission,&#xD;
             including: (1) Alanine aminotransferase (ALT) &gt; 1.5 x upper limit of normal (ULN), (2)&#xD;
             Aspartate aminotransferase (AST) &gt; 1.5 x ULN, (3) Bilirubin (total) &gt; 1.5 x ULN, (4)&#xD;
             Gamma glutamyl transpeptidase (GGT) &gt; 1.5 x ULN. (5) If any of these tests are&#xD;
             out-of-range, the tests can be repeated once.&#xD;
&#xD;
          5. Any clinically significant abnormal findings in vital signs at the Screening Visit&#xD;
             and/or admission to the Clinical Unit, including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
        (1) Heart rate (resting, supine) &lt; 50 beats per minute (bpm) or &gt; 85 bpm, (2) Systolic BP &lt;&#xD;
        90 mmHg or &gt; 140 mmHg and/or diastolic BP &lt; 50 mmHg or &gt; 90 mmHg sustained for &gt; 10 min&#xD;
        while resting in a supine position.&#xD;
&#xD;
        6. Any clinically significant abnormalities on 12-lead Electrocardiogram (ECG) at the&#xD;
        Screening Visit, including, but not limited to any of the following:&#xD;
&#xD;
          1. ECG interval measured from the onset of the QRS complex to the end of the T wave (QT)&#xD;
             interval corrected for heart rate using Fridericia's formula (QTcF) &gt; 450 ms or &lt; 340&#xD;
             ms or family history of long QT syndrome,&#xD;
&#xD;
          2. Any significant arrhythmia,&#xD;
&#xD;
          3. Conduction abnormalities:&#xD;
&#xD;
          4. Clinically significant PR (PQ) interval prolongation (&gt; 240 ms); intermittent second&#xD;
             or third degree atrioventricular (AV) block, or AV dissociation,&#xD;
&#xD;
          5. Complete bundle branch block and/or QRS duration &gt; 120 ms. 7. Any positive result at&#xD;
             the Screening Visit for serum hepatitis B surface antigen or antiHBc antibody,&#xD;
             hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
        8. Suspicion or known Gilbert's and/or Lesch-Nyhan syndrome. 9. Known or suspected history&#xD;
        of alcohol or drug abuse or excessive intake of alcohol as judged by the PI. Excessive&#xD;
        intake of alcohol defined as the regular consumption of more than 24 g of alcohol per day&#xD;
        for men or 12 g of alcohol per day for women.&#xD;
&#xD;
        10. Has received another new chemical entity (defined as a compound which has not been&#xD;
        approved for marketing in the US) within 30 days or at least 5 half-lives (whichever is&#xD;
        longer) of the first administration of verinurad in this study.&#xD;
&#xD;
        11. Participants who have previously received verinurad. 12. Plasma donation within 1 month&#xD;
        of screening or any blood donation/loss of more than 500 mL during the 3 months prior to&#xD;
        the Screening Visit.&#xD;
&#xD;
        13. Participants who are pregnant, lactating or planning to become pregnant. 14. History of&#xD;
        severe allergy/hypersensitivity or ongoing clinically relevant allergy/hypersensitivity, as&#xD;
        judged by the PI or history of hypersensitivity to drugs with a similar chemical structure&#xD;
        or class to verinurad.&#xD;
&#xD;
        15. Current smokers or those who have smoked or used nicotine products (including&#xD;
        e-cigarettes) within the 3 months prior to screening.&#xD;
&#xD;
        16. Excessive intake of caffeine-containing drinks or food (e.g., coffee, tea, chocolate)&#xD;
        as judged by the PI. Excessive intake of caffeine defined as regular consumption of more&#xD;
        than 600 mg of caffeine per day (e.g., &gt; 5 cups of coffee) or would likely be unable to&#xD;
        refrain from the use of caffeine containing beverages during confinement at the&#xD;
        investigational site.&#xD;
&#xD;
        17. Positive screen for drugs of abuse or cotinine (nicotine) at the Screening Visit or&#xD;
        positive screen for alcohol, drugs of abuse and cotinine on each admission to the study&#xD;
        centre.&#xD;
&#xD;
        18. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks&#xD;
        prior to the first administration of verinurad.&#xD;
&#xD;
        19. Use of any prescribed or non-prescribed medication including antacids, analgesics&#xD;
        (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to&#xD;
        600 times the recommended daily dose) and minerals during the 2 weeks prior to the first&#xD;
        administration of verinurad or longer if the medication has a long half-life. The use of&#xD;
        hormonal contraception therapy and hormonal replacement therapy for females are permitted.&#xD;
&#xD;
        20. Any AstraZeneca, PAREXEL or study site employee or their close relatives. 21.&#xD;
        Participants who cannot communicate reliably with the PI and/or is not able to read, speak&#xD;
        and understand the German language.&#xD;
&#xD;
        22. Judgment by the PI that the participant should not participate in the study if they&#xD;
        have any ongoing or recent (i.e., during the screening period) minor medical complaints&#xD;
        that may interfere with the interpretation of study data or are considered unlikely to&#xD;
        comply with study procedures, restrictions, and requirements.&#xD;
&#xD;
        23. Vulnerable participants, e.g., kept in detention, protected adults under guardianship,&#xD;
        trusteeship, or committed to an institution by governmental or juridical order.&#xD;
&#xD;
        24. Participants with any special dietary restrictions such as participants that are&#xD;
        lactose intolerant or are vegetarians/vegans.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D5495C00005&amp;amp;attachmentIdentifier=47483f56-39b2-4098-ae5a-75c4996ee4eb&amp;amp;fileName=d5495c00005_clinical_study_protocol_redacted.pdf&amp;amp;versionIdentifier=</url>
    <description>redacted CSP and SAP</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <results_first_submitted>August 4, 2020</results_first_submitted>
  <results_first_submitted_qc>August 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2020</results_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>URAT1 inhibitor</keyword>
  <keyword>Uric acid transporter 1</keyword>
  <keyword>Verinurad</keyword>
  <keyword>Crossover study</keyword>
  <keyword>Relative bioavailability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verinurad</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT04024501/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects signed and dated the informed consent form (ICF) before any study procedures were performed.</recruitment_details>
      <pre_assignment_details>The study included a Screening Period of maximum 28 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall-All Subjects</title>
          <description>All subjects were randomized into 5-period, 5-treatment, crossover study to receive a single oral dose of 12 mg verinurad:&#xD;
Treatment 1: 1 x 12 mg verinurad ER8 capsule formulation, fasted.&#xD;
Treatment 2: 2 x 6 mg verinurad A-capsule formulation, fasted.&#xD;
Treatment 3: 2 x 6 mg verinurad A-capsule formulation, fed.&#xD;
Treatment 4: 2 x 6 mg verinurad B-capsule formulation, fasted.&#xD;
Treatment 5: 2 x 6 mg verinurad B-capsule formulation, fed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall-All Subjects</title>
          <description>All subjects were randomized into 5-period, 5-treatment, crossover study to receive a single oral dose of 12 mg verinurad:&#xD;
Treatment 1: 1 x 12 mg verinurad ER8 capsule formulation, fasted.&#xD;
Treatment 2: 2 x 6 mg verinurad A-capsule formulation, fasted.&#xD;
Treatment 3: 2 x 6 mg verinurad A-capsule formulation, fed.&#xD;
Treatment 4: 2 x 6 mg verinurad B-capsule formulation, fasted.&#xD;
Treatment 5: 2 x 6 mg verinurad B-capsule formulation, fed.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.1" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC)</title>
        <description>To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions.</description>
        <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
        <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: 1 x 12 mg ER8 Capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 2 x 6 mg A-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 2 x 6 mg A-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2 x 6 mg B-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 2 x 6 mg B-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC)</title>
          <description>To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions.</description>
          <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.3" spread="47.60"/>
                    <measurement group_id="O2" value="167.5" spread="33.72"/>
                    <measurement group_id="O3" value="87.14" spread="65.84"/>
                    <measurement group_id="O4" value="149.0" spread="39.78"/>
                    <measurement group_id="O5" value="150.2" spread="42.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 2/Treatment 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean ratio</param_type>
            <param_value>106.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.73</ci_lower_limit>
            <ci_upper_limit>122.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 3/Treatment 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>50.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.34</ci_lower_limit>
            <ci_upper_limit>59.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 3/Treatment 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>47.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>39.85</ci_lower_limit>
            <ci_upper_limit>55.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 3/Treatment 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>58.40</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49.49</ci_lower_limit>
            <ci_upper_limit>68.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 4/Treatment 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>85.65</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.78</ci_lower_limit>
            <ci_upper_limit>99.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 4/Treatment 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>80.65</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>69.48</ci_lower_limit>
            <ci_upper_limit>93.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 5/Treatment 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>89.88</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.61</ci_lower_limit>
            <ci_upper_limit>104.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 5/Treatment 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>84.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72.94</ci_lower_limit>
            <ci_upper_limit>98.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 5/Treatment 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>179.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>151.57</ci_lower_limit>
            <ci_upper_limit>212.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 5/Treatment 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>104.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.18</ci_lower_limit>
            <ci_upper_limit>122.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC From Time 0 to the Last Quantifiable Concentration (AUC0-t) for the Analysis of PK Parameter</title>
        <description>To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions.</description>
        <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
        <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: 1 x 12 mg ER8 Capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 2 x 6 mg A-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 2 x 6 mg A-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2 x 6 mg B-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 2 x 6 mg B-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Time 0 to the Last Quantifiable Concentration (AUC0-t) for the Analysis of PK Parameter</title>
          <description>To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions.</description>
          <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.8" spread="47.57"/>
                    <measurement group_id="O2" value="167.5" spread="35.96"/>
                    <measurement group_id="O3" value="67.04" spread="80.37"/>
                    <measurement group_id="O4" value="128.5" spread="49.29"/>
                    <measurement group_id="O5" value="139.6" spread="44.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 2/Treatment 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>100.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.94</ci_lower_limit>
            <ci_upper_limit>118.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 3/Treatment 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>41.26</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>34.74</ci_lower_limit>
            <ci_upper_limit>49.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 3/Treatment 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>41.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>34.61</ci_lower_limit>
            <ci_upper_limit>48.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 3/Treatment 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>53.55</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>45.09</ci_lower_limit>
            <ci_upper_limit>63.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 4/Treatment 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>77.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>65.19</ci_lower_limit>
            <ci_upper_limit>91.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 4/Treatment 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>76.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>64.94</ci_lower_limit>
            <ci_upper_limit>90.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 5/Treatment 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>84.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>70.93</ci_lower_limit>
            <ci_upper_limit>100.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 5/Treatment 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>83.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>70.65</ci_lower_limit>
            <ci_upper_limit>99.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 5/Treatment 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>204.16</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>171.22</ci_lower_limit>
            <ci_upper_limit>243.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 5/Treatment 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>109.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.06</ci_lower_limit>
            <ci_upper_limit>129.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) for the Analysis of PK Parameter</title>
        <description>To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions.</description>
        <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
        <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: 1 x 12 mg ER8 Capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 2 x 6 mg A-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 2 x 6 mg A-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2 x 6 mg B-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 2 x 6 mg B-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) for the Analysis of PK Parameter</title>
          <description>To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions.</description>
          <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.51" spread="53.66"/>
                    <measurement group_id="O2" value="31.88" spread="62.41"/>
                    <measurement group_id="O3" value="8.243" spread="81.12"/>
                    <measurement group_id="O4" value="23.39" spread="66.08"/>
                    <measurement group_id="O5" value="17.02" spread="54.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 2/Treatment 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>124.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>101.09</ci_lower_limit>
            <ci_upper_limit>154.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 3/Treatment 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>33.77</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.15</ci_lower_limit>
            <ci_upper_limit>42.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 3/Treatment 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>27.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.72</ci_lower_limit>
            <ci_upper_limit>33.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 3/Treatment 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>36.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.61</ci_lower_limit>
            <ci_upper_limit>45.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 4/Treatment 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>91.69</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>74.15</ci_lower_limit>
            <ci_upper_limit>113.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 4/Treatment 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>73.36</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>59.33</ci_lower_limit>
            <ci_upper_limit>90.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 5/Treatment 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>67.62</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>54.37</ci_lower_limit>
            <ci_upper_limit>84.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 5/Treatment 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>54.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>43.50</ci_lower_limit>
            <ci_upper_limit>67.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 5/Treatment 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>200.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>160.15</ci_lower_limit>
            <ci_upper_limit>250.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison: Treatment 5/Treatment 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>73.76</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>59.30</ci_lower_limit>
            <ci_upper_limit>91.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC From Time 0 to 24 Hours Post Dose (AUC0-24) for the Analysis of PK Parameter</title>
        <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
        <time_frame>Pre-dose and up to 24-hours Post-dose</time_frame>
        <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: 1 x 12 mg ER8 Capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 2 x 6 mg A-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 2 x 6 mg A-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2 x 6 mg B-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 2 x 6 mg B-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Time 0 to 24 Hours Post Dose (AUC0-24) for the Analysis of PK Parameter</title>
          <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
          <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.6" spread="48.40"/>
                    <measurement group_id="O2" value="138.5" spread="39.67"/>
                    <measurement group_id="O3" value="54.85" spread="80.02"/>
                    <measurement group_id="O4" value="102.9" spread="54.45"/>
                    <measurement group_id="O5" value="110.6" spread="47.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) for the Analysis of PK Parameter</title>
        <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
        <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
        <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: 1 x 12 mg ER8 Capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 2 x 6 mg A-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 2 x 6 mg A-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2 x 6 mg B-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 2 x 6 mg B-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) for the Analysis of PK Parameter</title>
          <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
          <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.98" lower_limit="3.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="4.98" lower_limit="2.98" upper_limit="6.02"/>
                    <measurement group_id="O3" value="5.00" lower_limit="3.00" upper_limit="10.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="7.98" lower_limit="4.00" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) for the Analysis of PK Parameter</title>
        <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
        <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
        <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: 1 x 12 mg ER8 Capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 2 x 6 mg A-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 2 x 6 mg A-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2 x 6 mg B-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 2 x 6 mg B-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) for the Analysis of PK Parameter</title>
          <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
          <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.02" spread="4.732"/>
                    <measurement group_id="O2" value="13.61" spread="5.748"/>
                    <measurement group_id="O3" value="13.42" spread="5.549"/>
                    <measurement group_id="O4" value="14.36" spread="5.477"/>
                    <measurement group_id="O5" value="12.40" spread="5.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for the Analysis of PK Parameter</title>
        <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
        <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
        <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: 1 x 12 mg ER8 Capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 2 x 6 mg A-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 2 x 6 mg A-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2 x 6 mg B-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 2 x 6 mg B-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for the Analysis of PK Parameter</title>
          <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
          <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Litre/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.86" spread="42.15"/>
                    <measurement group_id="O2" value="75.43" spread="25.71"/>
                    <measurement group_id="O3" value="160.5" spread="86.96"/>
                    <measurement group_id="O4" value="86.26" spread="32.22"/>
                    <measurement group_id="O5" value="87.10" spread="41.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRT) for the Analysis of PK Parameter</title>
        <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
        <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
        <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: 1 x 12 mg ER8 Capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 2 x 6 mg A-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 2 x 6 mg A-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2 x 6 mg B-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 2 x 6 mg B-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRT) for the Analysis of PK Parameter</title>
          <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
          <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.98" spread="4.006"/>
                    <measurement group_id="O2" value="15.52" spread="5.843"/>
                    <measurement group_id="O3" value="17.43" spread="4.974"/>
                    <measurement group_id="O4" value="16.61" spread="6.049"/>
                    <measurement group_id="O5" value="18.28" spread="4.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Last Quantifiable Plasma Concentration (Tlast) for the Analysis of PK Parameter</title>
        <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
        <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
        <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: 1 x 12 mg ER8 Capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 2 x 6 mg A-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 2 x 6 mg A-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2 x 6 mg B-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 2 x 6 mg B-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Last Quantifiable Plasma Concentration (Tlast) for the Analysis of PK Parameter</title>
          <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
          <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.65" lower_limit="47.67" upper_limit="72.93"/>
                    <measurement group_id="O2" value="48.47" lower_limit="36.00" upper_limit="72.05"/>
                    <measurement group_id="O3" value="47.97" lower_limit="35.97" upper_limit="72.07"/>
                    <measurement group_id="O4" value="48.03" lower_limit="35.57" upper_limit="73.08"/>
                    <measurement group_id="O5" value="48.03" lower_limit="47.77" upper_limit="72.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State (Intravenous Dosing) (Vss/F) for the Analysis of PK Parameter</title>
        <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
        <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
        <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: 1 x 12 mg ER8 Capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 2 x 6 mg A-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 2 x 6 mg A-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2 x 6 mg B-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 2 x 6 mg B-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Intravenous Dosing) (Vss/F) for the Analysis of PK Parameter</title>
          <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
          <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1275" spread="612.8"/>
                    <measurement group_id="O2" value="1190" spread="586.4"/>
                    <measurement group_id="O3" value="2756" spread="1577"/>
                    <measurement group_id="O4" value="1472" spread="855.9"/>
                    <measurement group_id="O5" value="1645" spread="1157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for the Analysis of PK Parameter</title>
        <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
        <time_frame>Day 1: Pre-dose and up to 72-hour Post-dose</time_frame>
        <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: 1 x 12 mg ER8 Capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 2 x 6 mg A-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 2 x 6 mg A-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2 x 6 mg B-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 2 x 6 mg B-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for the Analysis of PK Parameter</title>
          <description>To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.</description>
          <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1529" spread="953.1"/>
                    <measurement group_id="O2" value="1490" spread="779.9"/>
                    <measurement group_id="O3" value="3120" spread="2066"/>
                    <measurement group_id="O4" value="1810" spread="1120"/>
                    <measurement group_id="O5" value="1719" spread="1608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>To assess AEs as variable of safety and tolerability of single doses of verinurad in healthy participants.</description>
        <time_frame>From screening (Day -28 to Day -2) till follow-up visit (7 to 14 days post-final dose)</time_frame>
        <population>All subjects who received at least 1 dose of verinurad (any formulation) were included in the safety analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: 1 x 12 mg ER8 Capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 2 x 6 mg A-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 2 x 6 mg A-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2 x 6 mg B-capsule Fasted</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 2 x 6 mg B-capsule Fed</title>
            <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>To assess AEs as variable of safety and tolerability of single doses of verinurad in healthy participants.</description>
          <population>All subjects who received at least 1 dose of verinurad (any formulation) were included in the safety analysis for the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment emergent adverse event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious TEAE (including death)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE leading to discontinuation of IMP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE leading to withdrawal from study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening (Day -28 to Day -2) till follow-up visit (7 to 14 days post-final dose)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment 1: 1 x 12 mg ER8 Capsule Fasted</title>
          <description>During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.</description>
        </group>
        <group group_id="E2">
          <title>Treatment 2: 2 x 6 mg A-capsule Fasted</title>
          <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.</description>
        </group>
        <group group_id="E3">
          <title>Treatment 3: 2 x 6 mg A-capsule Fed</title>
          <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.</description>
        </group>
        <group group_id="E4">
          <title>Treatment 4: 2 x 6 mg B-capsule Fasted</title>
          <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.</description>
        </group>
        <group group_id="E5">
          <title>Treatment 5: 2 x 6 mg B-capsule Fed</title>
          <description>During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>This confidential document is the property of AstraZeneca AB. No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca AB. Access to this document must be restricted to relevant parties.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca information Centre</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

